CA3034589A1 - Method for producing antibody fusion protein - Google Patents
Method for producing antibody fusion protein Download PDFInfo
- Publication number
- CA3034589A1 CA3034589A1 CA3034589A CA3034589A CA3034589A1 CA 3034589 A1 CA3034589 A1 CA 3034589A1 CA 3034589 A CA3034589 A CA 3034589A CA 3034589 A CA3034589 A CA 3034589A CA 3034589 A1 CA3034589 A1 CA 3034589A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- antibody
- acid sequence
- seq
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016164901 | 2016-08-25 | ||
| JP2016-164901 | 2016-08-25 | ||
| PCT/JP2017/030470 WO2018038243A1 (ja) | 2016-08-25 | 2017-08-25 | 抗体融合蛋白質の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3034589A1 true CA3034589A1 (en) | 2018-03-01 |
Family
ID=61246169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3034589A Pending CA3034589A1 (en) | 2016-08-25 | 2017-08-25 | Method for producing antibody fusion protein |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11512135B2 (enExample) |
| EP (1) | EP3505538B1 (enExample) |
| JP (2) | JP6993814B2 (enExample) |
| KR (1) | KR102318480B1 (enExample) |
| CN (1) | CN109641971B (enExample) |
| AU (1) | AU2017316955B2 (enExample) |
| BR (1) | BR112019003622A2 (enExample) |
| CA (1) | CA3034589A1 (enExample) |
| MX (1) | MX389073B (enExample) |
| SG (1) | SG11201901495YA (enExample) |
| WO (1) | WO2018038243A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10759864B2 (en) | 2016-12-26 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| US11248045B2 (en) | 2015-06-24 | 2022-02-15 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody permeating blood-brain barrier |
| US12214007B2 (en) | 2016-12-26 | 2025-02-04 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein including BDNF |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932699B2 (en) | 2017-09-07 | 2024-03-19 | Jcr Pharmaceuticals Co., Ltd. | Aqueous pharmaceutical composition |
| WO2019070577A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
| JP2019137675A (ja) * | 2018-02-05 | 2019-08-22 | Jcrファーマ株式会社 | 薬剤を筋肉に送達するための方法 |
| EP3560945A1 (en) * | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
| WO2019224660A1 (ja) * | 2018-05-24 | 2019-11-28 | HOYA Technosurgical株式会社 | 吸着剤の生産方法 |
| KR102692543B1 (ko) * | 2018-10-26 | 2024-08-07 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
| MA71661A (fr) | 2020-10-14 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées |
| US20240301069A1 (en) * | 2020-12-23 | 2024-09-12 | Guangdong Fapon Biopharma Inc. | Anti-PD-L1 Antibody and Usethereof |
| MA71665A (fr) * | 2021-02-11 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation |
| BR112023018268A2 (pt) | 2021-03-09 | 2023-10-31 | Japan Chem Res | Método para produzir uma proteína de fusão |
| KR20240125957A (ko) * | 2021-12-28 | 2024-08-20 | 제이씨알 파마 가부시키가이샤 | 안전한 유전자 치료를 위한 항트랜스페린 수용체 항체와 생리 활성을 갖는 단백질의 융합 단백질 |
| WO2024010067A1 (ja) * | 2022-07-08 | 2024-01-11 | Jcrファーマ株式会社 | 中枢神経系疾患の治療のための、核酸分子、ベクター、組換え細胞及び薬剤 |
| WO2025137213A1 (en) | 2023-12-20 | 2025-06-26 | Denali Therapeutics Inc. | Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1670931A2 (en) * | 2003-09-05 | 2006-06-21 | GTC Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| AR051805A1 (es) * | 2004-12-21 | 2007-02-07 | Centocor Inc | Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos |
| US20110105734A1 (en) | 2006-12-06 | 2011-05-05 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human erythropoietin |
| CN101622274A (zh) * | 2006-12-12 | 2010-01-06 | 比奥雷克西斯药物公司 | 转铁蛋白融合蛋白库 |
| JP2009273427A (ja) | 2008-05-16 | 2009-11-26 | Jcr Pharmaceuticals Co Ltd | 組換え体ヒトfshの製造方法 |
| CA2739568C (en) | 2008-10-31 | 2015-12-01 | Shujun Sun | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
| HRP20190690T1 (hr) | 2009-10-09 | 2019-06-28 | Armagen, Inc. | Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu |
| JP6018572B2 (ja) | 2011-01-25 | 2016-11-02 | Jcrファーマ株式会社 | 組換えヒトイズロン酸−2−スルファターゼの製造方法 |
| WO2012101671A1 (en) | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| RU2014126482A (ru) * | 2011-12-01 | 2016-01-27 | Ангиочем Инк. | Нацеленные соединения ферментов и их применение |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| WO2014016873A1 (en) * | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Method for production of recombinant human alpha-galactosidase a |
| WO2015098989A1 (ja) | 2013-12-25 | 2015-07-02 | Jcrファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| JP6071018B2 (ja) | 2014-10-31 | 2017-02-01 | Jcrファーマ株式会社 | 組換えヒトDNaseIの製造方法 |
| WO2016116966A1 (en) | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
-
2017
- 2017-08-25 MX MX2019002252A patent/MX389073B/es unknown
- 2017-08-25 EP EP17843719.0A patent/EP3505538B1/en active Active
- 2017-08-25 BR BR112019003622-9A patent/BR112019003622A2/pt unknown
- 2017-08-25 JP JP2017161826A patent/JP6993814B2/ja active Active
- 2017-08-25 CA CA3034589A patent/CA3034589A1/en active Pending
- 2017-08-25 CN CN201780051299.5A patent/CN109641971B/zh active Active
- 2017-08-25 SG SG11201901495YA patent/SG11201901495YA/en unknown
- 2017-08-25 KR KR1020197007992A patent/KR102318480B1/ko active Active
- 2017-08-25 AU AU2017316955A patent/AU2017316955B2/en active Active
- 2017-08-25 US US16/327,982 patent/US11512135B2/en active Active
- 2017-08-25 WO PCT/JP2017/030470 patent/WO2018038243A1/ja not_active Ceased
-
2021
- 2021-12-10 JP JP2021200504A patent/JP7232889B2/ja active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| US11248045B2 (en) | 2015-06-24 | 2022-02-15 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody permeating blood-brain barrier |
| US11958905B2 (en) | 2015-06-24 | 2024-04-16 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| US10759864B2 (en) | 2016-12-26 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| US11111308B2 (en) | 2016-12-26 | 2021-09-07 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| US12145995B2 (en) | 2016-12-26 | 2024-11-19 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| USRE50240E1 (en) | 2016-12-26 | 2024-12-24 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| US12214007B2 (en) | 2016-12-26 | 2025-02-04 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein including BDNF |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018038243A1 (ja) | 2018-03-01 |
| EP3505538A1 (en) | 2019-07-03 |
| SG11201901495YA (en) | 2019-03-28 |
| AU2017316955A1 (en) | 2019-03-21 |
| EP3505538B1 (en) | 2024-05-01 |
| KR20190040040A (ko) | 2019-04-16 |
| BR112019003622A2 (pt) | 2019-05-21 |
| EP3505538A4 (en) | 2020-03-18 |
| JP2018033454A (ja) | 2018-03-08 |
| US20190225700A1 (en) | 2019-07-25 |
| CN109641971B (zh) | 2023-04-04 |
| JP6993814B2 (ja) | 2022-01-14 |
| KR102318480B1 (ko) | 2021-10-28 |
| MX389073B (es) | 2025-03-20 |
| US11512135B2 (en) | 2022-11-29 |
| JP7232889B2 (ja) | 2023-03-03 |
| AU2017316955B2 (en) | 2022-03-03 |
| JP2022028959A (ja) | 2022-02-16 |
| MX2019002252A (es) | 2019-07-04 |
| CN109641971A (zh) | 2019-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11512135B2 (en) | Method for producing antibody fusion protein | |
| US11932699B2 (en) | Aqueous pharmaceutical composition | |
| EP3563863B1 (en) | Lyophilized preparation | |
| TWI787942B (zh) | 通過血腦障壁之抗人類運鐵蛋白受體抗體 | |
| US20240165258A1 (en) | Stable Aqueous Pharmaceutical Composition or Freeze-Dried Pharmaceutical Composition | |
| US20240158436A1 (en) | Method for Producing Antibody-Lysosomal Enzyme Fusion Protein | |
| HK40004497A (en) | Method for producing antibody fusion protein | |
| HK40100771A (en) | Method for producing antibody-lysosomal enzyme fusion protein | |
| HK40103835A (en) | Stable aqueous pharmaceutical composition or freeze-dried pharmaceutical composition | |
| HK40008948B (en) | Lyophilized preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220721 |
|
| EEER | Examination request |
Effective date: 20220721 |
|
| EEER | Examination request |
Effective date: 20220721 |
|
| EEER | Examination request |
Effective date: 20220721 |